Home / Stocks / Cohance Lifesciences Ltd
COHANCE

Cohance Lifesciences Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹459.45

Change

+3.05 (0.67%)

Open

₹458.0

Prev. Close

₹456.4

Day High

₹460.0

Day Low

₹451.05

Volume Analysis

Traded

247,273

Delivered

119,739

Delivery %

48.42%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (2)

  • •Low return on equity (4.89%)
  • •Promoter holding is falling

Opportunities (1)

  • •Strong 3-year revenue growth (19.2%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹471.56 ₹465.78 ₹462.61 ₹456.83 ₹453.66 ₹447.88 ₹444.71
Fibonacci ₹465.78 ₹462.36 ₹460.25 ₹456.83 ₹453.41 ₹451.3 ₹447.88
Camarilla ₹461.91 ₹461.09 ₹460.27 ₹456.83 ₹458.63 ₹457.81 ₹456.99

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-12.23%

1 Week

-2.59%

1 Month

-0.51%

3 Months

-0.77%

6 Months

+9.77%

1 Year

-21.04%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹103.64

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

-0.17%

Net margin -0.29% × asset turnover 0.4x × equity multiplier 1.45x

Company Overview

Sector

Healthcare

Market Cap

₹17,511 Cr

P/E (TTM)

359.0

ROE

4.89%

Book Value

₹102.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Cohance Lifesciences Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 50/100. The strongest factor is Financial Strength (100/100), while Valuation (22/100) is the weakest area to weigh before deciding. Notably: Low return on equity (4.89%); promoter holding is falling. FII holding has been falling.

TopFund Score — Fundamentals Quality

50/100 — Average

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

46

Valuation

22

Cash Flow

51

Corporate Governance

43

Momentum

54

Institutional Ownership

50

Business Quality

37

Risk & Volatility

33

Liquidity

56

From Screener.in

  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has low interest coverage ratio.
  • −Company has a low return on equity of 10.6% over last 3 years.
  • −Promoters have pledged 94.6% of their holding.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 231 220 253 488 604 676 840 549 556 545 619 422 477
Expenses + 133 154 180 363 398 439 611 437 435 449 520 421 441
Operating Profit 98 66 73 125 205 237 229 112 121 95 99 1 35
OPM % 42.4% 30.06% 29.0% 25.63% 34.01% 35.1% 27.27% 20.39% 21.77% 17.51% 15.94% 0.27% 7.42%
Other Income + 20 14 17 19 16 22 -4 6 16 1 -18 12 12
Interest 1 2 2 10 10 11 10 10 9 9 9 7 8
Depreciation 12 13 17 31 38 44 54 45 44 47 51 50 50
Profit before tax 105 65 71 103 174 205 161 63 84 41 20 -43 -11
Tax % 24.51% 28.59% 24.67% 26.85% 20.62% 24.97% 27.18% 26.07% 20.75% 28.52% 58.26% 5.41% -121.12%
Net Profit + 80 47 53 75 138 153 117 46 66 29 8 -45 2
EPS in Rs 3 2 2 3 5 6 5 1 2 1 1 -1 0
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -17 -38 -32 40 161 208 232 13 -8 -19 -26 -23 -14

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 378 834 1,010 1,320 1,340 1,051 2,608 2,269 2,063
Expenses + 206 449 567 738 766 645 1,811 1,841 1,832
Operating Profit 172 385 443 582 574 406 797 427 231
OPM % 45.0% 46.0% 44.0% 44.0% 43.0% 39.0% 31.0% 19.0% 11.0%
Other Income + 1 66 68 133 46 62 53 4 8
Interest 3 23 12 9 13 7 41 37 33
Depreciation 12 24 32 39 48 55 167 187 198
Profit before tax 158 405 468 668 560 406 643 207 7
Tax % 31.0% 22.0% 23.0% 32.0% 27.0% 26.0% 25.0% 27.0% —
Net Profit + 109 317 362 454 411 300 484 150 -6
EPS in Rs — 12 14 18 16 12 19 5 1
Dividend Payout % 0.0% 20.0% 14.0% 28.0% 37.0% 0.0% 0.0% 0.0% —
Sales growth — 121 21 31 2 -22 148 -13 -21

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 578 832 1,155 1,502 1,710 2,025 3,623 3,873 3,874
Borrowings + 83 186 143 97 70 65 486 400 448
Other Liabilities + 123 142 151 205 160 138 1,346 1,415 1,320
Total Liabilities 783 1,173 1,474 1,830 1,966 2,254 5,480 5,727 5,680
Fixed Assets + 271 357 441 534 663 670 3,107 3,369 3,399
CWIP 111 102 96 30 165 179 334 178 216
Investments 7 338 542 598 536 904 337 529 451
Other Assets + 394 376 395 667 601 501 1,702 1,652 1,614
Total Assets 783 1,173 1,474 1,830 1,966 2,254 5,480 5,727 5,680
Equity Capital 0 13 25 25 25 25 25 38 38

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 50 407 383 330 457 358 673 368
Cash from Investing Activity + -65 -413 -311 -136 -195 -362 -388 -251
Cash from Financing Activity + 26 7 -76 -156 -242 -14 -327 -165
Net Cash Flow 11 1 -5 37 20 -18 -42 -48
Free Cash Flow -6 304 272 255 171 307 357 169
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 49 128 111 88 105 115 107 102

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 60.0% → 57.48%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 13.93% 23.11% 22.67% 22.26% 22.37% 22.24% 14.95% 15.16% 14.91% 15.11% 15.92% 15.95%
Promoters 60.0% 50.1% 50.1% 50.1% 50.1% 50.1% 66.41% 57.49% 57.49% 57.49% 57.49% 57.48%
Government 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.0%
FII 10.14% 9.54% 9.8% 10.7% 10.84% 11.05% 7.23% 6.51% 6.01% 5.59% 6.5% 7.71%
DII 15.94% 17.24% 17.42% 16.95% 16.67% 16.6% 11.4% 20.81% 21.57% 21.79% 20.09% 18.86%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Cohance Lifesciences Ltd (this stock) 17,511 359.0 4.49 4.89%
Dr Agarwals Health Care L 17,460 97.5 7.8 6.41%
Pfizer Ltd 17,601 115.0 12.74 19.8%
Shilpa Medicare Ltd 17,616 55.1 6.39 9.3%
Alivus Life Sciences Ltd 17,803 50.6 — —
Caplin Point Lab Ltd. 17,863 25.9 4.58 20.9%
Molbio Diagnostics Ltd 17,111 236.0 11.89 15.6%

Which Mutual Funds Hold Cohance Lifesciences Ltd?

Frequently Asked Questions about Cohance Lifesciences Ltd

Community Sentiment

What are other investors saying about Cohance Lifesciences Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.